News >

CDK4/6 Inhibitors, Alpelisib Continue to Show Benefit in HR+/HER2- Breast Cancer

Gina Columbus @ginacolumbusonc
Published: Tuesday, Jan 29, 2019

Kevin Kalinsky, MD

Kevin Kalinsky, MD

Updated data with CDK4/6 and PI3K inhibitors showing progression-free and overall survival (OS) benefits are transforming the hormone receptor (HR)–positive, HER2-negative breast cancer arena, according to Kevin Kalinsky, MD, MS.

“HR-positive, HER2-negative breast cancer is the most common type of breast cancer that we see, and we have a landscape in which we are adding in targeted drugs, CDK4/6 inhibitors, and an mTOR inhibitor,” said Kalinsky, an assistant professor of medicine, Department of Medicine, at Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian Hospital/Columbia University Medical Center.

The 3 FDA-approved CDK4/6 inhibitors—palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio)—have continued to demonstrate efficacy and improvements in progression-free survival (PFS) in select patients with HR-positive, HER2-negative disease. Most recently, results from the PALOMA-3 trial showed that the combination of palbociclib plus fulvestrant (Faslodex) led to a clinically meaningful benefit in OS in some patients with advanced breast cancer who had progressed or relapsed on prior endocrine therapy.1 The regimen showed a 10.0-month OS improvement in patients who were sensitive to previous endocrine therapy.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication